Head to Head Comparison: NewGenIvf Group (NASDAQ:NIVF) versus Bausch + Lomb (NYSE:BLCO)

Bausch + Lomb (NYSE:BLCO) and NewGenIvf Group (NASDAQ:NIVF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Volatility and Risk

Bausch + Lomb has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500.

Institutional & Insider Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 0.8% of Bausch + Lomb shares are held by insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Bausch + Lomb and NewGenIvf Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$4.79 billion	1.26	-$317.00 million	($0.87)	-19.55
NewGenIvf Group	$5.43 million	0.09	-$520,000.00	N/A	N/A

NewGenIvf Group has lower revenue, but higher earnings than Bausch + Lomb.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Bausch + Lomb and NewGenIvf Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	2	8	5	0	2.20
NewGenIvf Group	1	0	0	0	1.00

Bausch + Lomb currently has a consensus price target of $17.00, suggesting a potential downside of 0.06%. Given Bausch + Lomb’s stronger consensus rating and higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than NewGenIvf Group.

Profitability

This table compares Bausch + Lomb and NewGenIvf Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-6.13%	2.42%	1.15%
NewGenIvf Group	N/A	N/A	N/A

Summary

Bausch + Lomb beats NewGenIvf Group on 8 of the 12 factors compared between the two stocks.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.